Suppr超能文献

局部晚期宫颈癌患者高剂量率近距离放疗剂量计算方法的回顾性评估:AcurosBV与美国医学物理师协会(AAPM)TG43形式主义的比较

Retrospective assessment of HDR brachytherapy dose calculation methods in locally advanced cervical cancer patients: AcurosBV vs. AAPM TG43 formalism.

作者信息

Radcliffe Billie Ann, Kim Yongbok, Raffi Julie, Ayala-Peacock Diandra N, Stephens Sarah J, Chino Junzo, Meltsner Sheridan, Craciunescu Oana

机构信息

Department of Radiation Oncology, Cape Fear Valley Health, Fayetteville, North Carolina, USA.

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.

出版信息

J Appl Clin Med Phys. 2025 Jan;26(1):e14549. doi: 10.1002/acm2.14549. Epub 2024 Oct 9.

Abstract

PURPOSE

This retrospective analysis was completed to investigate the use of a model-based dose calculation algorithm (MBDCA) AcurosBV, for use in HDR BT treatments for locally advanced cervical cancer treated with tandem and ovoid applicators with interstitial needles.

METHODS

A cohort of 32 patients receiving post-EBRT HDR brachytherapy boost with a prescription dose of 5.5 Gy × 5 fractions to the high-risk clinical target volume (CTV) were selected for this study. For standard TG43 dose calculation, applicators were manually digitized on the planning images, while for AcurosBV calculations, solid renderings of Titanium Fletcher Suite Delclos (FSD) applicators included in BrachyVision were matched to those used clinically and Ti needles were manually digitized. The dose was recalculated using Varian's AcurosBV 13.5 and dose-to-medium-in-medium (D) was reported. EQD2 values for targets and organs at risk were compared between dose calculation formalisms. D and D values were reported for the high and intermediate-risk CTVs, and values were reported for OARs including bladder, rectum, sigmoid, bowel, and vagina. Due to variability within the patient cohort, the dosimetric impact of AcurosBV was investigated corresponding to planning image modality (CT vs. CBCT), presence of Ti needles, and contrast within vaginal balloons used to stabilize implants. AcurosBV showed lower dosimetric values for all plans compared to TG43.

RESULTS

The average ± standard deviation of dosimetric reduction in D was 4.33 ± 0.09% for CTV and 4.12 ± 0.09% for CTV. The reduction to OARs was: 4.99 ± 0.15% for bladder, 7.87 ± 0.16% for rectum, 5.79 ± 0.17% for sigmoid, 6.91 ± 0.14% for bowel, and 4.55 ± 0.14% for vagina.

CONCLUSIONS

AcurosBV should be utilized for HDR BT GYN cases, treated with tandem and ovoid applicators, with high degrees of heterogeneity and calculated in tandem with TG43.

摘要

目的

本回顾性分析旨在研究基于模型的剂量计算算法(MBDCA)AcurosBV在使用串联和卵圆形施源器及间质针治疗局部晚期宫颈癌的高剂量率后装治疗(HDR BT)中的应用。

方法

本研究选取了32例接受外照射后高剂量率后装治疗强化的患者,其高危临床靶区(CTV)的处方剂量为5.5 Gy×5次分割。对于标准的TG43剂量计算,在计划图像上手动将施源器数字化,而对于AcurosBV计算,将BrachyVision中包含的钛制弗莱彻套装德尔克洛(FSD)施源器的实体渲染与临床使用的施源器进行匹配,并手动将钛针数字化。使用瓦里安的AcurosBV 13.5重新计算剂量,并报告介质中剂量到介质(D)。比较两种剂量计算方法下靶区和危及器官的等效均匀剂量(EQD2)值。报告高危和中危CTV的D和D值,以及包括膀胱、直肠、乙状结肠、肠和阴道在内的危及器官的 值。由于患者队列中的变异性,研究了AcurosBV的剂量学影响与计划图像模态(CT与CBCT)、钛针的存在以及用于稳定植入物的阴道球囊内的对比度之间的关系。与TG43相比,AcurosBV在所有计划中显示出更低的剂量学值。

结果

CTV的D剂量学降低的平均值±标准差为4.33±0.09%,CTV为4.12±0.09%。危及器官的降低值为:膀胱4.99±0.15%,直肠7.87±0.16%,乙状结肠5.79±0.17%,肠6.91±0.14%,阴道4.55±0.14%。

结论

对于使用串联和卵圆形施源器治疗的高剂量率后装治疗妇科病例,AcurosBV应与TG43串联计算,用于高度异质性的情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验